Ulla Klaiber

Ulla Klaiber

Auto-generated profile, based on publicly available information

Ulla Klaiber

Division of Visceral Surgery, Department of General Surgery, Medical University of Vienna , Vienna

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 August 2019 in British Journal of Surgery
Verified
Journal Article
Closed access
PDF file
Masayuki TanakaMasayuki Tanaka
Masayuki Tanaka
AMA. L. Mihaljevic
A. L. Mihaljevic
PPPascal Probst
Pascal Probst
MHM. Heckler
M. Heckler
UKU. Klaiber
U. Klaiber
Thilo HackertThilo Hackert
Thilo Hackert

7 February 2018 in British Journal of Surgery
Verified
Journal Article
Closed access
PDF file
UKU. Klaiber
U. Klaiber
PPPascal Probst
Pascal Probst
OSOliver Strobel
Oliver Strobel
CMC. W. Michalski
C. W. Michalski
CDC. Dörr-Harim
C. Dörr-Harim
Thilo HackertThilo Hackert
Thilo Hackert

26 June 2019 in British Journal of Surgery
Verified
Journal Article
Closed access
PDF file
Masayuki TanakaMasayuki Tanaka
Masayuki Tanaka
MHM. Heckler
M. Heckler
AMA. L. Mihaljevic
A. L. Mihaljevic
PPPascal Probst
Pascal Probst
UKU. Klaiber
U. Klaiber
Thilo HackertThilo Hackert
Thilo Hackert

2 September 2020 in BMJ Open
Verified
Journal Article
Open access
PDF file
UKUlla Klaiber
Ulla Klaiber
PSPeter Sauer
Peter Sauer
EMEike Martin
Eike Martin
TBThomas Bruckner
Thomas Bruckner
SLSteffen Luntz
Steffen Luntz
Thilo HackertThilo Hackert
Thilo Hackert
Introduction: Postoperative pancreatic fistula (POPF) is still the most frequently occurring and clinically relevant complication after distal pancreatectomy (DP). Preoperative endoscopic injection of botulinum toxin (BTX) into the sphincter of Oddi represents an innovative approach to prevent POPF. The aim of this project (PREBOT Pilot ) is to generate the first randomised controlled trial data on the safety, feasibility and efficacy of preoperative endoscopic BTX injection into the sphincter of Oddi to prevent clinically relevant POPF following DP. Methods and analysis: PREBOT Pilot is an investigator-initiated, single-centre, randomised, controlled, open-label, phase II clinical trial with two parallel study groups and an exploratory study design. 60 patients scheduled for DP will be randomised to intervention and control group. In the intervention group, patients will undergo preoperative endoscopic injection of BTX into the sphincter of Oddi, whereas in the control group no preoperative endoscopy will be performed. The combined primary endpoint is the occurrence of clinically relevant POPF and/or death within 30 days after DP. The secondary endpoints comprise further postoperative outcome parameters and quality of life up to 3 months after DP as well as safety and feasibility of the procedure. Statistical analysis is based on the modified intention-to-treat population, excluding patients without status post DP. For safety analysis, rates of adverse events (AEs) and serious AEs will be calculated with 95% CIs for group comparisons. Ethics, funding and dissemination: PREBOT Pilot has been approved by the German Federal Institute for Drugs and Medical Devices (reference number 4043654) and the Ethics Committee of Heidelberg University (reference number AFmo-523/2019). This trial is supported by the German Federal Ministry of Education and Research (BMBF). The results of the trial will be presented at national and international conferences and published in a peer-reviewed journal. Trial registration number: DRKS00020401.

1 November 2023 in BJS Open
Verified
Journal Article
Open access
PDF file
ANAnna Nießen
Anna Nießen
MLMartin Loos
Martin Loos
KNKatja Neumüller
Katja Neumüller
MFManuel Feißt
Manuel Feißt
UKUlla Klaiber
Ulla Klaiber
Thilo HackertThilo Hackert
Thilo Hackert
Ampullary carcinoma is a clinically variable entity. This study aimed to evaluate prognostic factors for the outcome of resected ampullary carcinoma patients with particular intent to analyse the influence of surgical radicality. Patients undergoing resection between 2002 and 2017 were analysed. Clinicopathological parameters, perioperative outcome and survival were examined. Risk factor analysis for postresection survival was performed. Resection margin status was evaluated according to the revised classification for pancreatic adenocarcinoma. A total of 234 patients were identified, 97.9 per cent (n = 229) underwent formal resection, while 2.1 per cent (n = 5) underwent ampullary resection. Histological subtypes were 46.6 per cent (n = 109) pancreatobiliary, 34.2 per cent (n = 80) intestinal, 11.5 per cent (n = 27) mixed, and 7.7 per cent (n = 18) undetermined. In the pancreatobiliary group, tumours were more advanced with more vascular resections, pT4 stage, G3 differentiation and pN+ status. Five-year overall survival was significantly different for pancreatobiliary compared to intestinal (51.7 per cent versus 72.8 per cent, P = 0.0087). In univariable analysis, age, pT4 stage, pN+, pancreatobiliary subtype and positive resection margin were significantly associated with worse overall survival. Long-term outcome was significantly better after true R0 resection (circumferential resection margin–, tumour clearance >1 mm) compared with circumferential resection margin+ (<1 mm) and R1 resections (5-year overall survival: 69.6 per cent, median overall survival 191 months versus 42.4 per cent and 53 months; P = 0.0017). Postresection survival of ampullary carcinoma patients is determined by histological subtype and surgical radicality. Intestinal differentiation is associated with less advanced tumour stages and better differentiation, which is reflected in a significantly better overall survival compared to pancreatobiliary differentiation. Despite this, true R0-resection is a prognostic key determinant in both entities, achieving 5-year survival in two-thirds of patients.

12 May 2026 in BJS Open
Verified
Journal Article
Open access
TSThomas Frederik Stoop
Thomas Frederik Stoop
CCChiara Croce
Chiara Croce
HIHiroyuki Ishida
Hiroyuki Ishida
MAMahsoem Ali
Mahsoem Ali
AJAmmar A Javed
Ammar A Javed
GKG Kazemier
G Kazemier
Background: The increased use of superior mesenteric artery (SMA) divestment has been a driver behind the increased resection rate for locally advanced pancreatic cancer following preoperative therapy. This has also resulted in an increase in the rate of postoperative neurogenic diarrhoea, but knowledge about postoperative neurogenic diarrhoea is lacking. The aims of this study were to determine the incidence, risk factors, management, and outcomes of neurogenic diarrhoea after SMA divestment/resection for pancreatic adenocarcinoma. Methods: This multicentre retrospective study included consecutive patients undergoing pancreatic adenocarcinoma resection, including SMA divestment/resection, after preoperative chemotherapy with or without radiotherapy between 2016 and 2022. Primary endpoints were the incidence of postoperative neurogenic diarrhoea, associated factors, treatment strategies, and outcomes. Secondary endpoints were the rate of adjuvant chemotherapy and the impact of neurogenic diarrhoea on overall survival (OS). Results: Overall, 291 patients who underwent pancreatic resection with concomitant SMA divestment (240, 82%) or resection (51, 18%) were included in the study. Postoperative neurogenic diarrhoea was diagnosed in 193 patients. The adjusted risk of developing neurogenic diarrhoea was 59% (95% confidence interval (c.i.) 46 to 73) after ≤ 180° SMA divestment, 80% (95% c.i. 67 to 93) after > 180° SMA divestment, and 77% (95% c.i. 66 to 88) after SMA resection. Postoperative neurogenic diarrhoea was treated with non-opioid drugs (29, 15%), non-opium opioids (140, 73%), opium tincture (69, 36%), and/or octreotide (49, 25%), and normalized in 51% of patients. After adjusting for confounders, neurogenic diarrhoea was not significantly associated with OS (hazard ratio 0.83; 95% c.i. 0.55 to 1.25). Conclusion: Neurogenic diarrhoea occurred in two-thirds of patients following resection of pancreatic adenocarcinoma with concomitant SMA divestment/resection, particularly after > 180° SMA divestment or SMA resection. Although challenging to manage, neurogenic diarrhoea is not associated with impaired OS. Evidence-based treatment strategies are needed for adequate management.